Pharming Group (NASDAQ:PHAR) Shares Gap Down - Should You Sell?

Key Points

• Pharming Group's stock price gapped down significantly on Tuesday, opening at $13.71 after closing at $14.90, representing a decline of 5.4%.
• The company reported $0.06 earnings per share for its last quarter, exceeding expectations, with revenues of $93.20 million, surpassing the consensus estimate of $70.36 million.
• An institutional investor, EverSource Wealth Advisors LLC, recently acquired a new position in Pharming Group, purchasing 2,979 shares valued at approximately $32,000.

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) gapped down prior to trading on Tuesday . The stock had previously closed at $14.90, but opened at $13.71. Pharming Group shares last traded at $14.39, with a volume of 2,819 shares trading hands.

Pharming Group Stock Up 1.7%

The business's fifty day moving average price is $11.69 and its 200 day moving average price is $10.17. The firm has a market capitalization of $1.04 billion, a price-to-earnings ratio of -116.38 and a beta of 0.05. The company has a current ratio of 2.79, a quick ratio of 2.07 and a debt-to-equity ratio of 0.38.

Pharming Group (NASDAQ:PHAR - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.16. Pharming Group had a negative net margin of 2.19% and a negative return on equity of 3.31%. The company had revenue of $93.20 million for the quarter, compared to the consensus estimate of $70.36 million. Pharming Group has set its FY 2025 guidance at EPS. On average, equities analysts expect that Pharming Group N.V. Sponsored ADR will post -0.2 EPS for the current year.

Hedge Funds Weigh In On Pharming Group

An institutional investor recently bought a new position in Pharming Group stock. EverSource Wealth Advisors LLC bought a new position in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 2,979 shares of the company's stock, valued at approximately $32,000. 0.03% of the stock is owned by hedge funds and other institutional investors.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.